|
AU2015202049A1
|
|
Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease
|
|
AU2013202407A1
|
|
Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease
|
|
AU2012202134A1
|
|
Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease
|
|
AU2007203067A1
|
|
Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease
|
|
AU5182500A
|
|
Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease
|
|
US6770279B1
|
|
TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
|
|
EP0980258A1
|
|
Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy
|
|
AU4959997A
|
|
Suppression of tnf alpha and il-12 in therapy
|
|
US6270766B1
|
|
Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
|
|
CA2225406A1
|
|
Methods for treatment and prevention of diabetes
|
|
US7608262B2
|
|
Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
|
|
EP0871641A1
|
|
Multiple administrations of anti-tnf antibody
|
|
EP0765171A1
|
|
Treatment of autoimmune and inflammatory disorders
|
|
WO9509652A1
|
|
Treatment of autoimmune and inflammatory disorders
|
|
AU5152293A
|
|
Treatment of autoimmune and inflammatory disorders
|
|
US5958409A
|
|
Method for treating multiple sclerosis
|
